Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?
-
Published:2024-06
Issue:6
Volume:11
Page:e392-e393
-
ISSN:2352-3026
-
Container-title:The Lancet Haematology
-
language:en
-
Short-container-title:The Lancet Haematology
Author:
Callander Natalie Scott
Reference10 articles.
1. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial;Rajkumar;Lancet Oncol,2010
2. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial;Voorhees;Lancet Haematol,2023
3. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma;Sonneveld;N Engl J Med,2024
4. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma;Costa;J Clin Oncol,2022
5. Triplet therapy, transplantation, and maintenance until progression in myeloma;Richardson;N Engl J Med,2022